Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03320018 · ClinicalTrials.gov registry record · Phase 2
Neuroprotection in Acute Ischemic Stroke
A Phase 2 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT03320018 is a Phase 2 study that has completed, run by Stony Brook University. The registered enrollment target is 15 participants.
The verdict
NCT03320018, a Phase 2 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a pilot randomized control trial (RCT) to explore the possible beneficial effect of a novel combination therapy consisting of molecular hydrogen H2 plus minocycline ("H2M"), on neurological recovery after acute ischemic stroke.
Interventions
- DRUG Hydrogen
- DRUG Minocycline
- OTHER Placebo Hydrogen
- OTHER Placebo Minocycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-08-02 |
| Est. Completion | 2019-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03320018
The ClinicalTrials.gov registry entry for NCT03320018 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Hydrogen is the first listed.
NCT03320018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03320018 about?
NCT03320018 is a clinical study titled "Neuroprotection in Acute Ischemic Stroke". This is a pilot randomized control trial (RCT) to explore the possible beneficial effect of a novel combination therapy consisting of molecular hydrogen H2 plus minocycline ("H2M"), on neurological recovery after acute ischemic stroke.
What is the current status of trial NCT03320018?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2017-08-02. Estimated completion is 2019-08-13.
What interventions are being tested in trial NCT03320018?
The interventions under investigation include: Hydrogen (DRUG), Minocycline (DRUG), Placebo Hydrogen (OTHER), Placebo Minocycline (OTHER).
Who is sponsoring clinical trial NCT03320018?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.